PURE earnings analysis
What we found in PURE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PURE Bioscience, Inc. reported a modest increase in revenue but faced significant challenges including a net loss and ongoing liquidity concerns. The company recorded revenues of $506,000 for the quarter ended April 30, 2026, marking a slight year-over-year increase, while also struggling with rising costs and decreased gross margins.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Year-over-Year
- Net product sales rose to $506,000 in Q3 2026 from $489,000 in Q3 2025, up by $17,000.
- Stable Gross Margin
- Gross margin percentage decreased slightly to 53% in Q3 2026 compared to 57% in Q3 2025 due to a change in product mix.
- Decreased SG&A Expenses
- Selling, general and administrative expenses fell by $68,000 from $776,000 in Q3 2025 to $708,000 in Q3 2026.
- Improved Cash Position
- Cash and cash equivalents rose to $983,000 as of April 30, 2026, up from $334,000 as of July 31, 2025.
- Increased Interest Expense
- Interest expense was $106,000 in Q3 2026, compared to $78,000 in Q3 2025, due to accrued interest on convertible notes.
- Management Changes
- CEO Robert Bartlett is set to retire on August 1, 2026, with Jeffrey Kitchell promoted to CEO.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity Concerns
- As of April 30, 2026, the company has a stockholder deficiency of $5,839,000 and recurring losses totaling $1,873,000 this period.
- Debt Servicing Costs
- Interest expense rose due to convertible notes; the company reported $301,000 in interest expense for the nine months ended April 30, 2026, up from $210,000 year-over-year.
- Going Concern Doubts
- Negative cash flows from operations and ongoing losses raise substantial doubt about the company's ability to continue as a going concern.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
- Gross margin
- 53%
What they said about what is next.
Management indicates severe liquidity constraints and the need for capital raises to fund operations, but avoids providing specific numeric guidance.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PURE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever